This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Teleflex (TFX) Q4 Earnings & Revenues Top Estimates, Margins Up
by Zacks Equity Research
Strong segmental performance in the domestic and international markets is driving Teleflex's (TFX) fourth-quarter top line.
Insulet (PODD) Q4 Earnings Surpass Estimates, Margins Up
by Zacks Equity Research
Insulet's (PODD) fourth-quarter 2021 revenues improved year over year on a strong performance of Omnipod, both in U.S. and international markets.
NuVasive (NUVA) Q4 Earnings Miss Estimates, Gross Margin Up
by Zacks Equity Research
Continued strong international performance and introduction of products drove NuVasive's (NUVA) revenues in the fourth quarter of 2021.
Amedisys (AMED) Q4 Earnings Top Estimates, Margins Decline
by Zacks Equity Research
Robust performances by the Home Health and Hospice segments drove Amedisys' (AMED) fourth-quarter top line.
Exact Sciences (EXAS) Q4 Revenues Top Estimates, Margin Down
by Zacks Equity Research
Exact Sciences' (EXAS) legacy Screening business saw strong momentum on solid Cologuard volume growth during the fourth quarter.
Tandem Diabetes (TNDM) Q4 Earnings Lag Estimates, Revenues Top
by Zacks Equity Research
Robust domestic and international pump shipments are driving Tandem Diabetes' (TNDM) fourth-quarter top line.
Charles River (CRL) DSA Arm Sees Growth, Cell Supply Sluggish
by Zacks Equity Research
The acquisitions of Cognate BioServices and Vigene Biosciences contribute to the growth of Charles River's (CRL) Manufacturing Solutions arm.
Henry Schein (HSIC) Up 10.1% Since Posting Q4 Earnings Beat
by Zacks Equity Research
Henry Schein (HSIC) stock rallies on strong fourth-quarter performance and bullish 2022 EPS guidance.
Syneos Health (SYNH) Q4 Earnings Top Estimates, Margins Down
by Zacks Equity Research
Syneos Health (SYNH) reports better-than-expected earnings for the fourth quarter and strong performances by the Clinical Solutions and Commercial Solutions arms.
Globus Medical (GMED) Q4 Earnings Top Estimates, Gross Margin Up
by Zacks Equity Research
Strength in Musculoskeletal Solutions and Enabling Technologies products drove Globus Medical's (GMED) Q4 revenues.
What Makes McKesson (MCK) a Strong Momentum Stock: Buy Now?
by Zacks Equity Research
Does McKesson (MCK) have what it takes to be a top stock pick for momentum investors? Let's find out.
Henry Schein (HSIC) Q4 Earnings Top Estimates, Margins Grow
by Zacks Equity Research
Robust performances by all three operating businesses drove Henry Schein's (HSIC) Q4 revenues.
Omnicell (OMCL) Q4 Earnings Miss Estimates, Revenues Beat
by Zacks Equity Research
Robust performance by the Product and Service segments is driving Omnicell's (OMCL) fourth-quarter top line.
Should Value Investors Buy These Medical Stocks?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
3 Reasons Why McKesson (MCK) Is a Great Growth Stock
by Zacks Equity Research
McKesson (MCK) is well positioned to outperform the market, as it exhibits above-average growth in financials.
If You Invested $1000 in McKesson 10 Years Ago, This Is How Much You'd Have Now
by Zacks Equity Research
Holding on to popular or trending stocks for the long-term can make your portfolio a winner.
Surging Earnings Estimates Signal Upside for McKesson (MCK) Stock
by Zacks Equity Research
McKesson (MCK) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Are These Medical Stocks a Great Value Stocks Right Now?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Zacks Investment Ideas feature highlights: Henry Schein, AmerisourceBergen and McKesson
by Zacks Equity Research
Henry Schein, AmerisourceBergen and McKesson are included in this Investment Ideas blog.
The Stock-Picking Puzzle: Putting The Pieces Together
by Bryan Hayes
The Stock-Picking Puzzle: Putting The Pieces Together
Company News for Feb 4, 2022
by Zacks Equity Research
Companies In The News Are: TMUS, MCK, ALL, AFL.
McKesson (MCK) Earnings and Revenues Beat Estimates in Q3
by Zacks Equity Research
McKesson's (MCK) fiscal third-quarter 2022 results benefit from considerable growth across all segments.
McKesson (MCK) Q3 Earnings and Revenues Top Estimates
by Zacks Equity Research
McKesson (MCK) delivered earnings and revenue surprises of 14.31% and 3.18%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?
Medical Products Stock Earnings on Feb 2: BSX, TMO & More
by Riya Anand
Medical Products companies' Q4 results are likely to reflect an increase in COVID-19 testing demand. Let's see how BSX, TMO, HOLX and MCK are poised ahead of their earnings releases.
McKesson (MCK) Hits 52-Week High: What's Aiding the Stock?
by Zacks Equity Research
Investors are optimistic about McKesson's (MCK) strength in its Biologics business.